Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Total Non-Current Liabilities (2016 - 2025)

Tandem Diabetes Care's Total Non-Current Liabilities history spans 13 years, with the latest figure at $676.2 million for Q4 2025.

  • For Q4 2025, Total Non-Current Liabilities rose 0.6% year-over-year to $676.2 million; the TTM value through Dec 2025 reached $676.2 million, up 0.6%, while the annual FY2025 figure was $676.2 million, 0.6% up from the prior year.
  • Total Non-Current Liabilities reached $676.2 million in Q4 2025 per TNDM's latest filing, down from $689.3 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $729.8 million in Q1 2025 to a low of $412.6 million in Q1 2021.
  • Average Total Non-Current Liabilities over 5 years is $598.5 million, with a median of $602.2 million recorded in 2022.
  • Peak YoY movement for Total Non-Current Liabilities: skyrocketed 272.17% in 2021, then decreased 0.15% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $454.2 million in 2021, then rose by 29.67% to $588.9 million in 2022, then grew by 3.1% to $607.2 million in 2023, then rose by 10.7% to $672.2 million in 2024, then grew by 0.6% to $676.2 million in 2025.
  • Per Business Quant, the three most recent readings for TNDM's Total Non-Current Liabilities are $676.2 million (Q4 2025), $689.3 million (Q3 2025), and $690.4 million (Q2 2025).